288 related articles for article (PubMed ID: 35249158)
21. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma.
Isaka M; Nakagawa K; Ohde Y; Okumura T; Watanabe R; Ito I; Nakajima T; Kondo H
Eur J Cardiothorac Surg; 2012 Apr; 41(4):841-6. PubMed ID: 22219429
[TBL] [Abstract][Full Text] [Related]
22. Molecular markers help characterize neuroendocrine lung tumors.
Rusch VW; Klimstra DS; Venkatraman ES
Ann Thorac Surg; 1996 Sep; 62(3):798-809; discussion 809-10. PubMed ID: 8784011
[TBL] [Abstract][Full Text] [Related]
23. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.
Kuo EJ; Salem RR
Ann Surg Oncol; 2013 Sep; 20(9):2815-21. PubMed ID: 23771245
[TBL] [Abstract][Full Text] [Related]
24. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
Shao N; Cai Q
Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
[TBL] [Abstract][Full Text] [Related]
25. Advances in neuroendocrine lung tumors.
Travis WD
Ann Oncol; 2010 Oct; 21 Suppl 7():vii65-71. PubMed ID: 20943645
[TBL] [Abstract][Full Text] [Related]
26. Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung.
Aly RG; Rekhtman N; Li X; Takahashi Y; Eguchi T; Tan KS; Rudin CM; Adusumilli PS; Travis WD
J Thorac Oncol; 2019 Sep; 14(9):1583-1593. PubMed ID: 31121325
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Tumor Markers for Predicting Disease-Free Survival in Surgically Resected Pancreatic Neuroendocrine Tumors.
Zhou B; Fang B; Yan S; Wang W
Clin Lab; 2017 Jul; 63(7):1251-1259. PubMed ID: 28792692
[TBL] [Abstract][Full Text] [Related]
28. [Relationship between preoperative inflammatory indexes and prognosis of patients with rectal cancer and establishment of prognostic nomogram prediction model].
Zhang L; Shi FY; Qin Q; Liu GX; Zhang HW; Yan J; Tan M; Wang LZ; Xue D; Hu CH; Zhang Z; She JJ
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):402-409. PubMed ID: 35615796
[No Abstract] [Full Text] [Related]
29. The prognostic value of multidetector CT features in predicting overall survival outcomes in patients with pancreatic neuroendocrine tumors.
Yang B; Chen HY; Zhang XY; Pan Y; Lu YF; Yu RS
Eur J Radiol; 2020 Mar; 124():108847. PubMed ID: 31991300
[TBL] [Abstract][Full Text] [Related]
30. Proposal of organ-specific subdivision of M component and staging system for metastatic pulmonary neuroendocrine tumor.
Wen J; Chen J; Liu D; Chen D; Chen Y; Fan M; Lu B
Lung Cancer; 2020 Oct; 148():86-93. PubMed ID: 32846318
[TBL] [Abstract][Full Text] [Related]
31. Automated quantification of Ki-67 index associates with pathologic grade of pulmonary neuroendocrine tumors.
Wang HY; Li ZW; Sun W; Yang X; Zhou LX; Huang XZ; Jia L; Lin DM
Chin Med J (Engl); 2019 Mar; 132(5):551-561. PubMed ID: 30807354
[TBL] [Abstract][Full Text] [Related]
32. Prognostic and diagnostic value of epithelial to mesenchymal transition markers in pulmonary neuroendocrine tumors.
Galván JA; Astudillo A; Vallina A; Crespo G; Folgueras MV; González MV
BMC Cancer; 2014 Nov; 14():855. PubMed ID: 25413006
[TBL] [Abstract][Full Text] [Related]
33. High vimentin expression with E-cadherin expression loss predicts a poor prognosis after resection of grade 1 and 2 pancreatic neuroendocrine tumors.
Zhou B; Xiang J; Jin M; Zheng X; Li G; Yan S
BMC Cancer; 2021 Mar; 21(1):334. PubMed ID: 33789624
[TBL] [Abstract][Full Text] [Related]
34. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
Zhang JT; Li Y; Yan LX; Zhu ZF; Dong XR; Chu Q; Wu L; Zhang HM; Xu CW; Lin G; Yu ZY; Hu J; Zhu B; Wang HJ; Yang F; Song ZB; Han ZB; Li MX; Lin J; Wu YL; Wang JL; Zhong WZ
Lung Cancer; 2020 Jan; 139():118-123. PubMed ID: 31775086
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung.
Morise M; Hishida T; Takahashi A; Yoshida J; Ohe Y; Nagai K; Ishii G
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2121-30. PubMed ID: 25963795
[TBL] [Abstract][Full Text] [Related]
36. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Deng M; Ma X; Liang X; Zhu C; Wang M
Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
[TBL] [Abstract][Full Text] [Related]
37. Neuroendocrine neoplasms of the lung: a prognostic spectrum.
Asamura H; Kameya T; Matsuno Y; Noguchi M; Tada H; Ishikawa Y; Yokose T; Jiang SX; Inoue T; Nakagawa K; Tajima K; Nagai K
J Clin Oncol; 2006 Jan; 24(1):70-6. PubMed ID: 16382115
[TBL] [Abstract][Full Text] [Related]
38. [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment].
Langfort R; Rudziński P; Burakowska B
Pneumonol Alergol Pol; 2010; 78(1):33-46. PubMed ID: 20162517
[TBL] [Abstract][Full Text] [Related]
39. The differences of biological behavior based on the clinicopathological data between resectable large-cell neuroendocrine carcinoma and small-cell lung carcinoma.
Kinoshita T; Yoshida J; Ishii G; Aokage K; Hishida T; Nagai K
Clin Lung Cancer; 2013 Sep; 14(5):535-40. PubMed ID: 23792008
[TBL] [Abstract][Full Text] [Related]
40. [Clinical Analysis of 22 Cases of Pulmonary Large Cell Neuroendocrine Cancer].
Qian Z; Hu Y; Zheng H; Dong Y; Wang Q; Li B
Zhongguo Fei Ai Za Zhi; 2016 Feb; 19(2):82-7. PubMed ID: 26903161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
